Regeneron (1REGN) Stock Forecast & Price Target

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1REGN Analyst Ratings

Moderate Buy

14 Buy

8 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1REGN Stock 12 Month Forecast

Average Price Target

€749.64

▲(7.12% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is €749.64 with a high forecast of €909.26 and a low forecast of €650.61. The average price target represents a 7.12% change from the last price of €699.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"516":"€516","713":"€713","910":"€910","614.5":"€614.5","811.5":"€811.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":909.2634515,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€909.26</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":749.6407679136363,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€749.64</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":650.60889685,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€650.61</span>\n  </div></div>","useHTML":true}}],"tickPositions":[516,614.5,713,811.5,910],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,663.7,682.5894962692308,701.4789925384616,720.3684888076923,739.2579850769231,758.1474813461539,777.0369776153847,795.9264738846155,814.8159701538461,833.7054664230769,852.5949626923077,871.4844589615384,890.3739552307693,{"y":909.2634515,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,663.7,670.310828301049,676.921656602098,683.5324849031468,690.1433132041958,696.7541415052448,703.3649698062937,709.9757981073426,716.5866264083916,723.1974547094405,729.8082830104895,736.4191113115384,743.0299396125873,{"y":749.6407679136363,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,663.7,662.6929920653846,661.6859841307693,660.6789761961538,659.6719682615385,658.664960326923,657.6579523923077,656.6509444576923,655.643936523077,654.6369285884615,653.6299206538462,652.6229127192307,651.6159047846154,{"y":650.60889685,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":519.538,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":564.905,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":653.666,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":655.061,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":638.126,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":669.404,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":666.412,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":599.791,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":517.292,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":551.852,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":640.048,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":702.5,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":663.7,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€909.26

Average Price Target€749.64

Lowest Price Target€650.61

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Evan Seigerman

BMO Capital

€706.22→€812.16

Buy

16.06%

Upside

Reiterated

10/01/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Akash Tewari

Jefferies

€768.02→€820.99

Buy

17.32%

Upside

Reiterated

10/01/26

Jefferies Sticks to Their Buy Rating for Regeneron (REGN)

Jasper Hellweg

Argus Research

€750.36

Buy

7.23%

Upside

Upgraded

09/30/26

Regeneron upgraded to Buy from Hold at ArgusRegeneron upgraded to Buy from Hold at Argus

Brian Abrahams

RBC Capital

€650.61

Hold

-7.03%

Downside

Reiterated

09/29/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Ocular Therapeutix (NASDAQ: OCUL) and Regeneron (NASDAQ: REGN)

Geoff Meacham

Citi

€653.26

Hold

-6.65%

Downside

Reiterated

09/28/26

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and Kodiak Sciences (NASDAQ: KOD)

Mohit Bansal

Wells Fargo

€662.09

Hold

-5.39%

Downside

Reiterated

09/28/26

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (NASDAQ: FDMT), Envista Holdings (NYSE: NVST) and Regeneron (NASDAQ: REGN)

Eve Burstein

Bernstein

€667.38

Hold

-4.63%

Downside

Reiterated

09/25/26

Regeneron (REGN) Receives a Hold from Bernstein

Chris Schott

J.P. Morgan

€794.5

Buy

13.53%

Upside

Reiterated

09/25/26

Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Regeneron (REGN)

Rajesh Kumar

HSBC

€706.22→€812.16

Buy

16.06%

Upside

Reiterated

09/10/26

Regeneron price target raised to $920 from $800 at HSBCRegeneron price target raised to $920 from $800 at HSBC

Louise Chen

Scotiabank

€679.74

Hold

-2.87%

Downside

Reiterated

08/20/26

Regeneron (REGN) Gets a Hold from Scotiabank

David Risinger

Leerink Partners

€565.86→€727.41

Hold

3.95%

Upside

Reiterated

08/17/26

Regeneron price target raised to $824 from $641 at LeerinkRegeneron price target raised to $824 from $641 at Leerink

Eliana Merle

Barclays

€809.51

Buy

15.68%

Upside

Reiterated

08/05/26

Barclays Keeps Their Buy Rating on Regeneron (REGN)

Yatin Suneja

Guggenheim

€882.78→€909.26

Buy

29.93%

Upside

Reiterated

08/03/26

Regeneron price target raised to $1,030 from $1,000 at GuggenheimRegeneron price target raised to $1,030 from $1,000 at Guggenheim

Gregory Renza

Truist Financial

€678.86→€681.51

Buy

-2.61%

Downside

Reiterated

07/31/26

Truist Financial Remains a Buy on Regeneron (REGN)

Terence Flynn

Morgan Stanley

€644.43→€669.15

Hold

-4.38%

Downside

Reiterated

07/31/26

Morgan Stanley Keeps Their Hold Rating on Regeneron (REGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Evan Seigerman

BMO Capital

€706.22→€812.16

Buy

16.06%

Upside

Reiterated

10/01/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Akash Tewari

Jefferies

€768.02→€820.99

Buy

17.32%

Upside

Reiterated

10/01/26

Jefferies Sticks to Their Buy Rating for Regeneron (REGN)

Jasper Hellweg

Argus Research

€750.36

Buy

7.23%

Upside

Upgraded

09/30/26

Regeneron upgraded to Buy from Hold at ArgusRegeneron upgraded to Buy from Hold at Argus

Brian Abrahams

RBC Capital

€650.61

Hold

-7.03%

Downside

Reiterated

09/29/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), Ocular Therapeutix (NASDAQ: OCUL) and Regeneron (NASDAQ: REGN)

Geoff Meacham

Citi

€653.26

Hold

-6.65%

Downside

Reiterated

09/28/26

Analysts Offer Insights on Healthcare Companies: Regeneron (NASDAQ: REGN) and Kodiak Sciences (NASDAQ: KOD)

Mohit Bansal

Wells Fargo

€662.09

Hold

-5.39%

Downside

Reiterated

09/28/26

Analysts Conflicted on These Healthcare Names: 4D Molecular Therapeutics (NASDAQ: FDMT), Envista Holdings (NYSE: NVST) and Regeneron (NASDAQ: REGN)

Eve Burstein

Bernstein

€667.38

Hold

-4.63%

Downside

Reiterated

09/25/26

Regeneron (REGN) Receives a Hold from Bernstein

Chris Schott

J.P. Morgan

€794.5

Buy

13.53%

Upside

Reiterated

09/25/26

Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Regeneron (REGN)

Rajesh Kumar

HSBC

€706.22→€812.16

Buy

16.06%

Upside

Reiterated

09/10/26

Regeneron price target raised to $920 from $800 at HSBCRegeneron price target raised to $920 from $800 at HSBC

Louise Chen

Scotiabank

€679.74

Hold

-2.87%

Downside

Reiterated

08/20/26

Regeneron (REGN) Gets a Hold from Scotiabank

David Risinger

Leerink Partners

€565.86→€727.41

Hold

3.95%

Upside

Reiterated

08/17/26

Regeneron price target raised to $824 from $641 at LeerinkRegeneron price target raised to $824 from $641 at Leerink

Eliana Merle

Barclays

€809.51

Buy

15.68%

Upside

Reiterated

08/05/26

Barclays Keeps Their Buy Rating on Regeneron (REGN)

Yatin Suneja

Guggenheim

€882.78→€909.26

Buy

29.93%

Upside

Reiterated

08/03/26

Regeneron price target raised to $1,030 from $1,000 at GuggenheimRegeneron price target raised to $1,030 from $1,000 at Guggenheim

Gregory Renza

Truist Financial

€678.86→€681.51

Buy

-2.61%

Downside

Reiterated

07/31/26

Truist Financial Remains a Buy on Regeneron (REGN)

Terence Flynn

Morgan Stanley

€644.43→€669.15

Hold

-4.38%

Downside

Reiterated

07/31/26

Morgan Stanley Keeps Their Hold Rating on Regeneron (REGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ONCBeOne Medicines

OVIDOvid Therapeutics

WSTWest Pharmaceutical Services

ZYMEZymeworks

SLDBSolid Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

3 Months

Yatin SunejaGuggenheim

Success Rate

11/16 ratings generated profit

Average Return

+4.02%

Copying Yatin Suneja's trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +4.02% per trade.

1 Year

Evan SeigermanBMO Capital

Success Rate

32/39 ratings generated profit

Average Return

+11.79%

Copying Evan Seigerman's trades and holding each position for 1 Year would result in 82.05% of your transactions generating a profit, with an average return of +11.79% per trade.

2 Years

Salveen RichterGoldman Sachs

Success Rate

13/19 ratings generated profit

Average Return

+8.92%

Copying Salveen Richter's trades and holding each position for 2 Years would result in 68.42% of your transactions generating a profit, with an average return of +8.92% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1REGN Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1REGN has received 9 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. 1REGN average Analyst price target in the past 3 months is 749.64.

Each month's total comprises the sum of three months' worth of ratings.

1REGN Financial Forecast

1REGN Earnings Forecast

Next quarter’s earnings estimate for 1REGN is €14.12 with a range of €12.83 to €15.61. The previous quarter’s EPS was €12.61. 1REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 1REGN has Performed in-line its overall industry.

1REGN Sales Forecast

Next quarter’s sales forecast for 1REGN is €4.01B with a range of €3.83B to €4.20B. The previous quarter’s sales results were €3.79B. 1REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 1REGN has Performed in-line its overall industry.

1REGN Stock Forecast FAQ

What is IT:1REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron’s 12-month average price target is 749.64.

What is IT:1REGN’s upside potential, based on the analysts’ average price target?

Regeneron has 7.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Regeneron a Buy, Sell or Hold?

Regeneron has a consensus rating of Moderate Buy, which is based on 14 buy ratings, 8 hold ratings and 0 sell ratings.

What is Regeneron’s share price target?

The average share price target for Regeneron is 749.64. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €909.26 ,and the lowest forecast is €650.61. The average share price target represents 7.12% Increase from the current price of €699.8.

What do analysts say about Regeneron?

Regeneron’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Regeneron?

To buy shares of IT:1REGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Regeneron (1REGN) Stock Forecast & Price Target

1REGN Analyst Ratings

1REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

1REGN Analyst Recommendation Trends

1REGN Financial Forecast

1REGN Earnings Forecast

1REGN Sales Forecast

1REGN Stock Forecast FAQ

Detailed List of Analyst Forecasts